Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

Rocco Capuano,Alvino Bisecco,Miriana Conte,Giovanna Donnarumma,Manuela Altieri,Elena Grimaldi,Gianluigi Franci,Annalisa Chianese,Massimiliano Galdiero,Nicola Coppola,Gioacchino Tedeschi,Antonio Gallo

Multiple Sclerosis and Related Disorders（2022）

引用 21|浏览16

暂无评分

摘要

•People with Multiple Sclerosis (pwMS) treated with Ocrelizumab (OCR) and Fingolimod (FNG) mount a blunted and shorter humoral response to BNT162b2 mRNA Covid-19 vaccine in pwMS treated with OCR and FNG when compared with HCs.•Humoral response in pwMS on OCR is associated with longer time-window since last OCR infusion up to six-month.•Humoral response in pwMS on FNG is associated with treatment duration, disease duration and absolute lymphocyte count up to six-month.

查看译文

关键词

Multiple sclerosis,Covid-19,SARS-CoV-2 mRNA vaccine,Ocrelizumab,Fingolimod,Long term humoral response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要